Fidelis Capital Partners LLC Sells 89 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fidelis Capital Partners LLC lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 888 shares of the company’s stock after selling 89 shares during the quarter. Fidelis Capital Partners LLC’s holdings in IDEXX Laboratories were worth $415,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Capital Research Global Investors purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth $135,910,000. American Century Companies Inc. boosted its holdings in shares of IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after purchasing an additional 177,226 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of IDEXX Laboratories by 178.8% during the 4th quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock valued at $144,317,000 after purchasing an additional 166,751 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $78,001,000. Finally, 1832 Asset Management L.P. increased its holdings in shares of IDEXX Laboratories by 4,193.1% in the second quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company’s stock worth $62,601,000 after purchasing an additional 125,498 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 0.2 %

Shares of IDXX opened at $507.66 on Tuesday. The company’s fifty day simple moving average is $484.35 and its 200-day simple moving average is $498.35. The company has a market cap of $41.93 billion, a P/E ratio of 49.14, a P/E/G ratio of 4.17 and a beta of 1.33. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.88 by ($0.44). The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The firm’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.67 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on IDXX shares. Stifel Nicolaus cut their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Finally, BTIG Research initiated coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $582.25.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.